GV Goldfield Corp

• Offering oversubscribed 4.7 times, for an overall demand of €93.9m1
• Price set at €15 per share (middle of the range)
• Full exercise of the Increase Option

Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 – GV) a molecular diagnostics company that specializes in the development of diagnostic tests for genetic diseases and cancers using the DNA molecular combing process, today announces the success of its initial public offering on the regulated market of Euronext in Paris (Compartment C).

Aaron Bensimon, Co-founder and Chairman of the Management Board of Genomic Vision, says: “We are delighted with the success of Genomic Vision’s IPO on compartment C of Euronext in Paris. On behalf of the entire team, I would like to thank all of our partners, historical shareholders and new shareholders who have chosen to put their trust in us and to contribute to this remarkable success. This successful stock-market listing reflects the efforts undertaken by our teams of researchers and staff that have helped make Genomic Vision the French pioneer in oncogenetics, and I would like to take this opportunity to thank them all. Thanks to the funds we have raised, Genomic Vision can confidently begin a new phase in its development based on the marketing of its tests in Europe, the enhanced throughput of its technological platform and the designing of new tests based on its innovative technology - unique in the world - for diagnosing genetic diseases and hereditary cancers.”

The Offering has met a great success among French and international institutional investors (the "Global Placement"), as well as among retail investors (the "OPO").

Given the strong demand recorded, i.e. €93.9m, the Company has decided to fully exercise the Increase Option. It was also decided to set the subscription price at €15per share, in the middle of the range.

Overall, the number of shares issued reaches 1,533,332 allowing a capital increase of €23.0m (including share premium) and excluding the exercise of the Overallotment Option (the number of shares offered could be increased by 229,999 shares).

All the new shares offered under the Offering will be allocated as follows:

- Global Placement: 1,303,332 shares allocated (approximately €19.5m and 85% of the total number of shares issued);

- Open Price Offering (OPO): 230,000 shares allocated (approximately €3.5m and 15% of the total number of shares issued);

- In respect of the OPO, A1 orders will be allocated at 28.4225% and A2 orders will be allocated at 0%.

Based on a total of 4.266.907 shares to be admitted to trading and a value of €15 per share, total market capitalization of the Company stands at €64.0m.

The settlement/delivery of newly issued shares under the Open Price Offering and the Global Placement will occur on April 4th, 2014. From the 2nd to the 4th of April 2014 (inclusive), the Company's shares will be traded in the form of promises of shares. The shares will be traded from April 7th, 2014. Shares are admitted to trading on Compartment C of the regulated market of Euronext in Paris under the ISIN code FR0011799907 and under the symbol GV.

In accordance with their subscription undertakings, Quest Diagnostics Ventures LLC and Vesalius Biocapital Holdings SA, historical shareholders of the Company, participated in the operation.

Use of proceeds

The proceeds from the IPO are intended to provide the Company with additional resources to finance its operations, more specifically, regardless of the net proceeds the Offering:

- to fund the development of sales in Europe, in particular costs connected to the establishment of a technical/sales team and to make molecular combing platforms available for clients;

- to finance ongoing projects aimed at improving the technological platform (industrialisation of the new high-throughput scanner, image analysis algorithms, etc.) with a view to reducing the time required for analysis and reviewing the results; and

- to support the R&D effort required to develop new products.

Timetable of the offering – upcoming dates

April 2nd, 2014  

■ Beginning of trading for the Company’s shares on the regulated marketof Euronext in Paris in the form of promises of shares

 

April 4th, 2014   ■ Settlement/delivery of the OPO and the Global Placement April 7th, 2014   ■ Beginning of trading for the Company’s shares on the regulated market of Euronext in Paris April 30th, 2014   ■ Deadline for the exercise of the Overallotment Option

■ End of the stabilisation period, as the case may be

Identification codes for Genomic Vision shares

• Company name : « Genomic Vision » (and « GENOMICVISION PROM » for promises shares that will be traded from April 2nd to April 4th, 2014 included)
• ISIN : FR0011799907
• Symbol : GV
• Compartment : Compartment C
• Sector : 4573 - Biotechnology (ICB classification)

Financial intermediaries

Bryan, Garnier & Co

 

Societe Generale

Joint Lead Managers and Joint Bookrunners

Sponsor Finance

Company Advisor

●●●

Availability of the prospectus – Copies of the prospectus, which received a visa from the AMF on March 19th, 2014 under the number 14-087, composed of the document de base filed with the AMF on March 3rd, 2014 under the number I. 14-005 and the note d’opération (including a summary of the prospectus), may be obtained free of charge at Genomic Vision’s headquarters, Green Square - Bâtiment E, 80-84 rue des Meuniers, 92220 Bagneux, from the internet websites of Genomic Vision (www.genomicvision.com) and the AMF (www.amf-france.org).

Risk factors – Genomic Vision draws the public's attention to chapter 4, “Risk factors”, of the document de base registered with the AMF, and to chapter 2 “Risk factors related to the Offering” of the note d’opération.

●●●

ABOUT GENOMIC VISIONA spinoff of the Institut Pasteur, Genomic Vision is a molecular diagnostics company specialized in developing diagnostic tests for genetic diseases and cancers. Using “molecular combing”, an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

ABOUT MOLECULAR COMBINGDNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if “combed”, and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient’s genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

Pour en savoir plus: http://www.genomicvision.com

DISCLAIMERThis press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

In particular:This press release does not constitute an offer to sell or any solicitation to purchase or subscribe for securities in the United States. The shares, or any other securities of GENOMIC VISION, may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended, or exempt from registration. The shares of GENOMIC VISION have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and GENOMIC VISION does not intend to make any public offer of its shares in the United States.

This press release is solely an advertisement and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, in particular, by Directive 2010/73/EC of the European Parliament and the Council of November 24th, 2010 and as implemented in each member State of the European Economic Area (the “Prospectus Directive”). With respect to the member States of the European Economic Area which have transposed the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to in this press release requiring a publication by GENOMIC VISION of a prospectus in any member State, other than France. As a result, the shares of GENOMIC VISION may not be offered or will not be offered in any member State other than France, except, pursuant to the exemptions described in article 3(2) of the Prospectus Directive, if they have been implemented by the relevant member State or in any other circumstances not requiring GENOMIC VISION to publish a prospectus as provided under article 3(2) of the Prospectus Directive and/or regulations applicable in such member State.

This press release is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The prospectus registered with the Autorité des Marchés Financiers contains forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in the prospectus, and to the development of economic conditions, the financial markets and the markets in which GENOMIC VISION operates.

Société Générale, acting as stabilising agent, or any institution acting on its behalf may, during a period of 30 days following the date on which the Offering Price is determined, i.e., according to the indicative timetable, from 1 April to 30 April 2014, effect transactions with a view to maintaining the market price of the GENOMIC VISION shares in a manner consistent with applicable laws and regulations and, in particular, EU Commission regulation number 2273/03 of 22 December 2003. These activities are intended to support the market price of the GENOMIC VISION shares and may affect the share price.

1 Before exercise of the Increase Option, and based on a price of €15 per share.

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN

Genomic VisionAaron BensimonCo-founder, President & CEOTel.: +33 1 49 08 07 50investors@genomicvision.comorNewCap.Investor Relations & Financial CommunicationsDušan Orešanský / Emmanuel HuynhTel.: +33 1 44 71 94 92gv@newcap.fr